SecBot SecBot
6-K ·Filed Jul 21, 2026

NVS

NOVARTIS AG
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001114448-26-000012
Notable filing: 6-K
Actionable Insight • Neutral

Results were in line with reaffirmed guidance, with core operating income flat in Q2. The key swing factors to watch are Entresto's continued generic erosion trajectory and the outcome of the Lutathera patent appeal. Pipeline catalysts in H2 include Kisqali overall survival data and regulatory decisions for Cosentyx in PMR and ianalumab in Sjögren's. The elevated debt load from M&A may limit near-term buyback acceleration.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

NVS drug pipeline →

Cosentyx

● Neutral Named in this 6-K
Impact
Phase
Approved (marketed); additional Phase 3 programs completed/terminated
Time to market
Already marketed — approved in the US since January 2015; label-expansion filings for PMR/GCA are possible but no submission or decision date is recorded.
Next catalyst
None dated

What to watchWatch for Novartis disclosures on the completed PMR (381 patients, primary completion Sept 2025) and GCA (354 patients) Phase 3 programs, a regulatory submission for either would be the next meaningful Cosentyx catalyst, though it would move a ~$156 mega-cap modestly. Also track IL-17 competition and any biosimilar entry, plus the next quarterly 6-K for Cosentyx sales trajectory.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$153.87
T+0 close · Jul 21, 2026 · via day close
Latest settled
−7.45%
T+60 · $142.41
Vs SPY
−11.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $153.87entry
  2. T+1 · 4mo ago −0.51%α −0.40% · $153.08
  3. T+5 · 4mo ago +1.46%α +2.68% · $156.11
  4. T+20 · 3mo ago +0.44%α −2.12% · $154.55
  5. T+60 · 5w ago −7.45%α −11.42% · $142.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novartis reported Q2 2026 net sales of $14.4B (+3% USD, +1% cc), with core operating income flat at $5.9B (0% cc). Net income declined -19% to $3.3B due to higher taxes and interest expense. Full-year guidance was reaffirmed: low single-digit net sales growth and low single-digit core operating income decline. Strong growth from Kisqali (+43% cc), Kesimpta (+32% cc), and Scemblix (+89% cc) was offset by generic erosion of Entresto (-51% cc). Net debt rose to $39.4B following the $12B Avidity acquisition.

Key Facts

  • Q2 net sales $14.4B (+3% USD, +1% cc); H1 net sales $27.5B (+1% USD, -2% cc)
  • Q2 core operating income $5.9B (flat cc); core EPS $2.41 (0% USD, -1% cc)
  • Q2 net income $3.3B (-19% cc); EPS $1.71 (-18% cc)
  • Q2 free cash flow $5.6B (-12%)
  • Full-year 2026 guidance reaffirmed: net sales low single-digit growth, core operating income low single-digit decline (cc)
  • Kisqali +43% cc, Kesimpta +32% cc, Scemblix +89% cc, Pluvicto +43% cc, Leqvio +59% cc
  • Entresto -51% cc due to US generic competition; Promacta -65% cc, Tasigna -58% cc
  • Lutathera patent invalidity ruling in Delaware; appeal filed
  • Avidity acquisition closed Feb 2026 for ~$12B; Pikavation ($1.8B) and Excellergy ($0.9B) closed in Q2
  • Net debt increased to $39.4B from $21.9B at Dec 2025; debt/equity ratio 1.12:1
  • Share buyback: $2.8B in H1 2026; $5.6B remaining under $10B program

Financial Impact

Q2 net sales +3% USD, operating income -2%, net income -19%. Core operating income flat. H1 net sales +1%, operating income -6%, net income -16%. Net debt increased $17.5B to $39.4B.

revenueoperating incomenet incomeepsfree cash flowdebt

Risk Factors

  • Lutathera patent invalidity ruling could open door to generic competition if appeal fails
  • Entresto sales declining ~50% YoY due to US generics, a major headwind to total revenue
  • Net debt of $39.4B and debt/equity ratio of 1.12:1 increase financial leverage
  • Higher interest expense ($462M in Q2 vs $289M) pressuring net income

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001114448-26-000012
Document: nvs-20260630-99_1.htm0001114448-26-000012
Document: nvs-20260630.htm0001114448-26-000012
Document: 0001114448-26-000012-index-headers.html0001114448-26-000012
Document: 0001114448-26-000012-index.html0001114448-26-000012
Document: 0001114448-26-000012.txt0001114448-26-000012

Track record

16 reports on NVS

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +6.86% at T+60 after the Jul 1, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 3/10 Entry $160.50 to $160.20 Now $160.20 −0.19% ▼ −0.19% +1.72% vs SPY
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $163.26 to $160.32 Now $160.20 −1.87% ▼ −1.80% −3.12% vs SPY
  3. Oct 28, 202619d ago 144 Neutral 2/10 Entry $156.08 to $161.10 Now $160.20 +2.64% ▲ +3.22% +3.60% vs SPY
  4. Oct 27, 202620d ago 6-K Mixed 6/10 Entry $156.86 to $156.08 Now $160.20 +2.13% ▼ −0.50% −0.84% vs SPY
  5. Oct 15, 20264w ago Court Ruling Neutral 2/10 Entry $150.62 to $150.20 Now $160.20 +6.36% ▼ −0.28% −0.70% vs SPY
  6. Oct 13, 20265w ago Court Ruling Bearish 5/10 Entry $146.88 to $150.38 Now $160.20 −9.07% ▼ −2.38% −2.10% vs SPY
  7. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $141.28 to $142.71 Now $160.20 +13.39% ▲ +1.01% +1.73% vs SPY
  8. Sep 4, 202610w ago 6-K Bearish 6/10 Entry $137.70 to $137.48 Now $160.20 −16.34% ▲ +0.16% −0.30% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $161.25 to $162.46 Now $160.20 −0.65% ▲ +0.75% +0.31% vs SPY
  10. Aug 4, 202615w ago Court Ruling Neutral 2/10 Entry $154.44 to $154.21 Now $160.20 +3.73% ▼ −0.15% +0.01% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 21, 2026